<DOC>
	<DOCNO>NCT00421304</DOCNO>
	<brief_summary>The primary objective study describe effect single dose medication compare placebo upper respiratory tract previously healthy child less equal 12 month age hospitalize low respiratory tract illness .</brief_summary>
	<brief_title>A Study Evaluate Single Intravenous Dose Motavizumab Treatment Children Hospitalized With Respiratory Syncytial Virus ( RSV ) Illness</brief_title>
	<detailed_description>The primary objective study describe effect single 30 mg/kg 100 mg/kg intravenous ( IV ) dose Motavizumab compare placebo study drug level viral load measure cultivatable virus real-time RT-PCR upper respiratory tract previously healthy child ≤12 month age hospitalize low respiratory tract illness .</detailed_description>
	<criteria>Children must meet following criterion : Previously healthy Age le equal 12 month time randomization Gestational age equal 36 week Hospitalized low respiratory tract illness ( i.e. , RSV bronchiolitis and/or pneumonia ) Documented positive RSV test within 48 hour prior randomization Randomization within 12 hour decision hospitalize child RSV illness Written inform consent obtain patient 's parent ( ) /legal guardian Children must none following : Prior receipt receive ribavirin antiviral treatment current episode RSV infection prior randomization Any use systemic inhale steroid within past 30 day prior randomization Intubation ventilatory support randomization Any medically significant underlie ongoing chronic illness organ system dysfunction , know acute illness except RSV infection Known renal impairment , hepatic dysfunction , hematologic abnormality , seizure neurologic disorder immunodeficiency Requirement supplemental oxygen time prior current RSV infection ( brief use oxygen immediate postnatal period treat transient condition allow ) Mechanical ventilation time prior onset current RSV infection Congenital heart disease [ child medically surgically closed patent ductus arteriosis ( PDA ) , small atrial septal defect ( ASD ) small ventricular septal defect ( VSD ) allow ] Previous reaction IVIG , blood product , foreign protein Prior use IVIG , palivizumab ( SynagisÒ ) , immunoglobulin product within past 2 month Currently receive investigational agent receive investigational agent within 3 month prior randomization Prior current participation investigational study therapeutic agent vaccine RSV</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>